A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Phase 2 Study to Evaluate the Efficacy and Safety of BMS-986263 in Adults With Compensated Cirrhosis From Nonalcoholic Steatohepatitis (NASH)
Latest Information Update: 06 Sep 2024
At a glance
- Drugs BMS-986263 (Primary)
- Indications Hepatic fibrosis; Liver cirrhosis
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 08 Mar 2024 This trial has been completed in France, according to the European Clinical Trials Database record
- 08 Mar 2024 This trial has been completed in Netharland, according to the European Clinical Trials Database record.
- 13 Feb 2024 Status changed from active, no longer recruiting to discontinued.